A novel broad-spectrum treatment for respiratory virus infections : influenza-based defective interfering virus provides protection against pneumovirus infection in vivo by Easton, A. J. (Andrew J.) et al.
 University of Warwick institutional repository: http://go.warwick.ac.uk/wrap 
 
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
Author(s):  Andrew J. Easton, Paul D. Scott,  Nicole L. Edworthy, Bo 
Meng, Anthony C. Marriott and Nigel J. Dimmock 
Article Title: A novel broad-spectrum treatment for respiratory virus 
infections: Influenza-based defective interfering virus provides 
protection against pneumovirus infection in vivo 
Year of publication: 2011 
Link to published article:  
http://dx.doi.org/10.1016/j.vaccine.2011.01.102 
Publisher statement:  NOTICE: this is the author’s version of a work 
that was accepted for publication in Vaccine. Changes resulting from 
the publishing process, such as peer review, editing, corrections, 
structural formatting, and other quality control mechanisms may not be 
reflected in this document. Changes may have been made to this work 
since it was submitted for publication. A definitive version was 
subsequently published in Vaccine Vol. 29(15), September 2011, DOI: 
10.1016/j.vaccine.2011.01.102 
 
  
 
 
 
 
A novel broad-spectrum treatment for respiratory virus infections: influenza-
based defective interfering virus provides protection against pneumovirus 
infection in vivo 
 
Andrew J. Easton*, Paul D. Scott, Nicole L. Edworthy, Bo Meng, Anthony C. Marriott, and 
Nigel J. Dimmock 
 
School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK 
 
 
 
 
*
 Corresponding author: Professor Andrew J. Easton, School of Life Sciences, University of 
Warwick, Coventry CV4 7AL, UK.  Tel:  +44 (0)2476 524727; Fax:  +44 (0)2476 523568 
 
Email address:  a.j.easton@warwick.ac.uk 
 
 
AJE and PDS contributed equally to the work 
 
 
 
Keywords:  defective interfering; protection; pneumovirus; influenza 
  
 2 
ABSTRACT 
Respiratory viruses represent a major clinical burden.  Few vaccines and antivirals are 
available, and the rapid appearance of resistant viruses is a cause for concern.  We have 
developed a novel approach which exploits defective viruses (defective interfering (DI) or 
protecting viruses).  These are naturally occurring deletion mutants which are replication-
deficient and multiply only when coinfection with a genetically compatible infectious virus 
provides missing function(s) in trans.  Interference/protection is believed to result primarily 
from genome competition and is therefore usually confined to the virus from which the DI 
genome originated.  Using intranasally administered protecting influenza A virus we have 
successfully protected mice from lethal in vivo infection with influenza A viruses from 
several different subtypes [1].  Here we report, contrary to expectation, that protecting 
influenza A virus also protects in vivo against a genetically unrelated respiratory virus, 
pneumonia virus of mice, a pneumovirus from the family Paramyxoviridae.  A single dose 
that contains 1 µg of protecting virus protected against lethal infection.  This protection is 
achieved by stimulating type I interferon and possibly other elements of innate immunity.  
Protecting virus thus has the potential to protect against all interferon-sensitive respiratory 
viruses and all influenza A viruses. 
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1. Introduction 
A wide range of viruses cause respiratory illness that is a major burden on the human 
population.  The severity of respiratory disease ranges from the approximately 40 million 
fatalities of the 1918 influenza pandemic to the mild rhinitis of the common cold.  Two 
groups of viruses responsible for large numbers of respiratory infections around the world are 
the influenza viruses (family Orthomyxoviridae) and the pneumoviruses (sub-family 
Pneumovirinae of the family Paramyxoviridae).  Both the Orthomyxoviridae and 
Paramyxoviridae have single-strand, negative sense RNA genomes, but are genetically 
distinct with the Orthomyxoviridae having segmented genomes while those of the 
Paramyxoviridae comprise a single molecule [2, 3].  Prophylaxis against influenza viruses is 
achieved through vaccines which have to be developed annually because of antigenic 
variation.  Antivirals (oseltamivir, zanamivir) are now seen as a significant weapon in the 
armoury in protecting against new outbreaks, but appearance of antiviral-resistant influenza 
viruses is a major concern [4, 5].  The only antiviral approved for treatment of human 
respiratory syncytial virus (Pneumovirinae), which is responsible for the highest level of 
hospitalisation of infants worldwide, is ribavirin.  However, ribavirin is not in general use 
clinically, and high-risk children are treated prophylactically with the monoclonal antibody 
palivizumab [6]. 
We have developed a new approach that harnesses defective-interfering (DI) viruses as 
antivirals.  The active principle is the DI genome which arises spontaneously from the 
genome of infectious virus and contains one or more major deletions.  This results in 
elimination of at least one essential gene and renders it defective for replication.  DI viruses 
are thus dependent on coinfection with the virus that gave rise to the DI genome or one with 
which it is genetically compatible to provide missing function(s) in trans.  Current thinking is 
that DI viruses reduce production of helper virus in cell culture probably as a result of the 
 4 
smaller DI genome having a competitive edge [7-11].  The DI virus particles retain receptor 
specificity and hence are targeted to the natural sites of infection in vivo.  DI viruses are 
produced with varying facility by nearly all virus families.  Influenza DI viruses were the first 
to be recognised [12-14], and while their molecular biology has been studied extensively [10, 
15, 16] analysis has been difficult as a single DI preparation can contain many different DI 
RNA sequences, which can arise from any of the 8 viral RNAs each with variably located 
central deletions [17, 18], although most arise from the three largest viral RNAs.  We have 
solved this heterogeneity problem by producing cloned viruses that contain one major species 
of DI RNA [1, 18-21], and have characterized 244 DI RNA, that is particularly active in 
protecting mice from a variety of different influenza A subtypes [1].  We have designated DI 
viruses that have demonstrable, reproducible, in vivo activity as ‘protecting viruses’ [22].  
The observed cross-subtype antiviral activity of DI virus 244/PR8 (244 RNA packaged by 
A/PR8), coupled with its replication dependence on infectious virus and the common genetic 
system of all influenza A viruses, suggest that it acts at the level of genome competition [8].  
Overall, however, the use of DI viruses to protect from infection in vivo has been 
disappointing, with very limited data showing that a few DI viruses can protect from clinical 
disease caused by their ‘parental’ virus [23-26]. 
It is well known that double stranded RNAs are efficient stimulators of type I interferon and, 
consistent with this, DI RNAs which have an extensively double stranded structure (such as 
the copyback and snapback DI RNAs of vesicular stomatitis virus and Sendai virus) also 
stimulate interferon type I [27-31].  However, there are no reports that the interferon 
stimulated by copyback or snapback DI RNAs can protect in vivo against genetically 
unrelated virus infections.  Influenza viruses do not produce copyback or snapback DI RNAs 
and influenza DI RNAs in general, and 244/PR8 DI RNA in particular, have no major regions 
of double-stranded sequence that would be expected to induce interferon.  However, it was 
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recently reported that during influenza infection of cells in vitro, the smaller influenza 
genomic RNAs and various DI RNAs become associated with the retinoic acid inducible gene 
1 (RIG-1) that contributes to interferon type I induction [32], although it was not possible to 
say which of the RNAs (genomic or DI) was responsible for activation of an interferon-
stimulated promoter and the luciferase gene under its control.  These data raise the possibility 
that influenza virus DI RNAs may be able to induce interferon in vivo and that this may 
contribute to protection from infection by other non-influenza A viruses.  In this way, DI 
RNAs might represent an additional weapon in the armoury for combatting virus infections. 
In this report we demonstrate that influenza DI virus 244/PR8 protects mice from respiratory 
infection caused by an unrelated paramyxovirus, pneumonia virus of mice (PVM).  PVM is a 
member of the genus Pneumovirus that includes human respiratory syncytial virus (HRSV), a 
particular problem to infants and the elderly, and is the recognised animal model for HRSV 
[33].  PVM is known to be a murine virus but is antigenically related to viruses that also occur 
in humans [34]. 
 
 
2. Materials and methods 
2.1. Viruses 
 
Defective interfering (DI) influenza A virus 244/PR8 arose spontaneously during generation 
of cloned virus by transfection of 293T cells with a set of influenza A/PR/8/34 (H1N1) 
plasmids [1].  The protecting 244/PR8 DI virus was amplified in MDCK cells and then in 
embryonated chicken’s eggs, and purified by centrifugation through sucrose.  Preparations 
were standardized to 2 x 10
5
 haemagglutination units (HAU)/ml and stored in liquid nitrogen.  
DI RNA 244 is 395 nucleotides in length and is derived from segment 1 RNA of influenza 
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strain A/PR/8/34 apparently by having undergone a single deletion.  It comprises nt 1-244 and 
2191-2341 of the A/PR8 minus-sense segment 1 RNA, and retains the original termini and 
sequences essential for replication and encapsidation.  Analysis by RT-PCR with primers 
specific for genome segment 1 showed that the 244 RNA was the major defective RNA 
present.  Helper virus infectivity was eliminated by irradiating with UV for 40 seconds at 
253.7 nm.  This has little effect on the DI RNA because of the small UV-target size of the 
protecting RNA (395 nucleotides) compared with the infectious viral genome (13,600 
nucleotides).  Prolonged UV irradiation (8 minutes) destroys the mouse-protecting activity but 
does not affect viral HA or neuraminidase (NA) activities [1], and provides a control for 
immune system-stimulating or receptor-blocking effects.  Influenza virus A/WSN/40 virus 
(H1N1) was also prepared in embryonated eggs.  Pneumonia virus of mice (PVM, 
Paramyxoviridae), strain J3666, was grown and assayed in BSC-1 cells. 
 
2.2. Animal studies 
 
C3H/He-mg mice (4-5 weeks-old, 16-20 g, bred in house) were inoculated intranasally under 
light ether anaesthesia with protecting 244/PR8 virus [35, 36].  Mice were infected 
intranasally with 10 LD50 PVM (250 infectious units) after anaesthesia with ketamine and 
xylazine.  PVM is highly pathogenic and its effects were monitored [37] by group weight and 
individual clinical disease according to the scheme: healthy mice score 1, ruffled fur with 
some deep breathing, and looking less alert score 2, obvious weight loss, with laboured 
breathing, and possible tremors score 3, abnormal gait, difficulty with walking, frequently 
emaciated, and may show cyanosis of tails and/or ears score 4, and death scores 5.  The 
percentage change in mouse group weight, normalized against the weight prior to treatment, 
was also recorded.  All animal experiments were carried out in accordance with the relevant 
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UK regulations and mice were culled if judged in severe distress in accordance with the 
requirements of the UK Home Office licence under which the work was performed.  
Interferon type I receptor-null mice (129Sv/Ev IFNα/βR-/- ;Banting and Kingman Ltd., UK) 
and wild type mice (129Sv/Ev; Charles River) were used as indicated.   
 
2.3. Assay of PVM lung infectivity in vitro 
 
Lungs from infected mice were stored at -70°C.  The right-hand lung of each subject was 
thawed, homogenised with sand and PBS containing 0.1% w/v BSA, and then centrifuged to 
remove debris.  Infectivity was titrated in BSC-1 cells using a focus-forming assay in 96-well 
plates.  Triplicate assays were incubated at 31°C for 72 hours. The cells were then fixed in 1:1 
(v/v) methanol: acetone, and blocked with 5% w/v milk powder in PBS.  Virus-positive cells 
were detected using a mouse monoclonal antibody specific to the PVM P protein [38], and 
goat anti-mouse IgG-alkaline phosphatase conjugate (Sigma), both in buffered saline 
containing 0.1% v/v Tween 20, and finally alkaline phosphatase substrate (NBT/BCIP in 
TMN buffer; Sigma).  At least 50 positively stained cells (foci) at an appropriate dilution were 
counted in each of three wells and averaged to give a titre in focus-forming units (FFU)/lung. 
 
2.4. Assay for interferon antiviral activity 
 
Lung samples were assayed for interferon type I activity in mouse L929 cells by challenge 
with Chandipura virus (CV; Rhabdoviridae) or Semliki Forest virus (SFV; Togaviridae).  The 
readout was reduction in virus-induced cytopathology.  Lungs were homogenized as above 
and clarified supernatant stored at -70°C.  For the assay of interferon, supernatant was serially 
2-fold diluted from 1/10 and added to cells for 24 hours at 37°C to allow for induction of the 
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antiviral state.  Cells were infected next day with challenge virus and incubated at 33°C.  
Putative virus-inhibitory interferon activity was recorded by staining surviving cells with 
crystal violet, and quantitating extracted stain on an ELISA reader.  Each plate contained a 
virus control, a cell control and an interferon type I standard.   The standards were 
recombinant mouse type 1 α and β interferons sourced from PBL Biomedical Laboratories.  
The interferon was identified using the same assay in which cells were first incubated with 
antibody (10µg/well for 1 hour at 37°C) to the external domain of the mouse interferon type I 
receptor (R&D Systems Inc., #WXB01). 
 
3. Results 
 
3.1. A single dose of DI influenza virus 244/PR8 protects mice from lethal infection with the 
paramyxovirus PVM 
 
We initially investigated the ability of a single dose of intranasally administered 244/PR8 (1.2 
µg per mouse) to protect C3H/He-mg mice against an intranasal lethal challenge with PVM, 
given 1 day later.  Control groups which received UV-inactivated, non-protective 244/PR8, 
followed by PVM, developed severe clinical signs and weight loss similar to those in the 
PVM-infected control group, and all died (Fig. 1a).  In contrast, protecting virus 244/PR8 
protected all animals against PVM-induced clinical disease (Fig. 1a) apart from a small 
reduction in weight on day 8 (Fig. 1c).  The remaining control groups, treated with 244/PR8 
alone, or mock-inoculated mice (not shown) displayed steady weight gain and no clinical 
disease (Fig. 1a, c).  A 10-fold lower dose of 244/PR8 (0.12 µg) gave some protection, 
delayed and ameliorated disease in some mice and enabled 40% to survive with subsequent 
weight gain.  The lowest dose tested (0.012 µg) was not protective (Fig. 1a, d).  These data 
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demonstrate that 244/PR8 is highly effective at protecting mice from an unrelated viral 
infection in a dose-responsive manner, and that the active principle central to protection is 
abrogated by prolonged UV irradiation, as we showed earlier with an influenza A virus 
challenge [1].  This is the first report demonstrating the ability of an influenza virus-derived 
DI virus to protect from disease caused by a completely unrelated virus in vivo.  Further 
analysis showed that multiplication of PVM in the lung was greatly reduced in infected mice 
treated with 244/PR8: infectivity was detected 2 days later in protected mice than in those 
treated with inactivated 244/PR8 or saline before PVM infection, and after 5 days PVM 
infectivity was reduced by 98.8% (Fig. 1b).  By 9 days after infection, PVM infectivity was 
undetectable in the protected group.  Mice in the PVM-infected control groups were all dead 
by day 7.   
 
3.2. Duration of prophylaxis afforded by DI influenza virus 244/PR8 on PVM infection 
 
Mice were treated with a single dose of 244/PR8 at 1, 3 and 7 days before challenge with a 
lethal dose of PVM strain J3666.  With treatment at 1 day before infection there was strong 
protection with only mild symptoms occurring during days 7-11 and some weight loss over 
days 8-10 (Fig. 2a, b).  Mice then recovered completely.  Treatment with 244/PR8 given 3 
days before infection with PVM gave significant protection with 40% of mice surviving (Fig. 
2c, d).  Treatment with 244/PR8 given 7 days before PVM challenge afforded no protection 
(data not shown).  Control mice challenged with PVM alone all died.  
 
3.3. Immune status of mice protected from PVM by a single dose of DI influenza virus 
244/PR8 
 
 10 
The detection of low levels of replication of the highly pathogenic PVM challenge raised the 
possibility that mice which had been successfully protected against PVM disease by treatment 
with 244/PR8 may have established a PVM-specific immune response.  The 244/PR8-
protected mice were rechallenged with intranasal PVM at 3 weeks after the first PVM 
infection, proved to be solidly immune and showed no clinical disease or weight loss, whereas 
all age-matched control mice died (data not shown).  Thus 244/PR8 converts the original 
PVM lethal challenge into a low level infection that induces a fully protective immune 
response. 
 
3.4. Therapeutic efficacy of a single dose of DI influenza virus 244/PR8 against PVM in vivo   
 
Therapeutic efficacy of 244/PR8 against PVM infection was tested by treating with a single 
dose of 244/PR8 at 0, 24, 48, and 72 hours after infection (Fig. 3a, b).  Inoculation of 
protecting virus at the same time as PVM challenge completely abrogated clinical disease and 
weight loss.  Mice given therapy at 24 hours after PVM infection showed a mild and short-
lived clinical disease and some weight loss over days 7-8, but made a 100% recovery.  
Therapy at 48 hours significantly reduced clinical disease and gave 50% survival.  Therapy at 
later times was not effective. 
 
3.5. A functional type I interferon response is required for DI influenza virus 244/PR8-
mediated protection against PVM in vivo 
 
There is no report in the literature for genetic interaction between the Orthomyxoviridae and 
Paramyxoviridae, and influenza protecting virus 244/PR8 does not interfere with the 
multiplication of PVM in vitro (data not shown).  A possible mechanism for the protection in 
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vivo is induction of type I interferon in vivo.  To investigate this we compared 244/PR8-
mediated protection in mice that lacked the common interferon type I receptor (129Sv/Ev 
IFNα/βR-/-) using the relevant wt mice (129Sv/Ev) as control.  Mice were inoculated with a 
single dose of either active or UV-inactivated 244/PR8 followed by PVM one day later.  Data 
show that wt (Fig. 4a, b) and interferon receptor knock-out mice (Fig. 4c, d) given inactivated 
244/PR8 followed by PVM all became ill by day 5 and were dead by day 9.  Treatment of wt 
mice with 244/PR8 delayed the onset and reduced the severity of clinical disease and weight 
loss.  All these mice resumed weight gain and recovered completely (Fig. 4a, b).  In 
comparison, 83% of type I interferon receptor knock-out mice treated with 244/PR8 died, 
although illness and weight loss were delayed by a few days (Fig. 4c, d).  These data indicate 
that type I interferon plays a key role in 244/PR8-mediated protection against PVM infection 
in vivo and demonstrate for the first time that interferon induction by an influenza virus-
derived DI stimulates sufficient levels of interferon in vivo to abrogate infection.  However, 
the 4-day delay in symptom onset caused by 244/PR8 in knock-out mice also suggests that 
protecting virus stimulates antiviral factor(s) other than interferon type I.  In contrast to the 
PVM scenario, 244/PR8 protected both wt (Fig. 4e, f) and interferon receptor knock-out mice 
(Fig. 4g, h) from an influenza A virus challenge (A/WSN), despite mice being treated and 
challenged simultaneously, giving less time for stimulation of interferon.  A/WSN-infected 
interferon receptor knock-out mice treated with 244/PR8 showed only a trace of clinical 
disease and a dip in weight gain that rapidly resolved.  Those given inactivated protecting 
virus all died (Fig. 4g, h).  These data clearly show that 244/PR8 protection against influenza 
virus is not reliant on the interferon response. 
 
3.6. Protecting virus 244/PR8, in the absence of challenge virus, induces type I interferon in 
the lungs of intranasally inoculated mice 
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Mice were inoculated intranasally with 12 µg of active 244/PR8 or UV-inactivated 244/PR8.  
None received any infectious challenge virus.  After 1 day, lungs were processed for an assay 
that measures the ability of interferon type I to protect L929 cells from a cytopathic virus 
challenge.  Lung extracts of mice inoculated with active 244/PR8 were positive for putative 
interferon activity (Table 1).  There was no evidence of antiviral activity in mice inoculated 
with 1.2 µg 244/PR8 (data not shown), or with UV inactivated 244/PR8.  In order to 
determine the duration of the antiviral activity mice were inoculated intranasally with active 
244/PR8 or UV inactivated 244/PR8 (12 µg per mouse) and lungs were removed 1, 2 and 4 
days later.  Again no challenge virus was given.  There was clear putative type I interferon 
activity in lung extracts taken on day 1 after inoculation, lower activity on day 2, and none on 
day 4 (≤1/10) (Table 2).  Again no detectable antiviral activity was stimulated by inactivated 
244/PR8 (data not shown). 
All type I α-interferons and β-interferon share the same cell surface transmembrane protein 
receptor, and interferon activity can be identified by blocking the receptor with antibody 
specific for the external binding domain.  Using the assay for antiviral activity described 
above, we incubated L929 cells with antibody specific for mouse interferon type I α/β 
receptor.  A lung extract containing previously identified antiviral activity stimulated in mice 
by administration of 244/PR8 (12 μg) was then added to the cells, and incubated overnight to 
induce an antiviral state.  Challenge virus was then added.  Each plate contained a virus 
control, cell control and a positive interferon control.  Fig. 5 shows that 244/PR8-induced 
antiviral activity in the lung completely inhibited the extensive cytopathology caused by the 
challenge virus.  However, when antibody to the interferon type I α/β receptor was present the 
antiviral activity was inhibited, confirming that protection was due to type I interferon.  Virus 
and cell controls without antibody performed as expected. 
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4. Discussion 
 
The conventional view of the mechanism of action of defective interfering viruses is that they 
act against genetically compatible viruses by competing at the level of genome replication.  
While that appears to be true in vitro, the data presented here show that this is not the full 
explanation for the mode of action of protection by DI viruses. 
Here we have shown that a DI influenza A virus, 244/PR8, can stimulate type I interferon in 
vivo in mice.  We have also demonstrated for the first time that DI 244/PR8 virus, can induce 
sufficient levels of interferon to confer protection in vivo against infection with an unrelated 
paramyxovirus, PVM.  Further, treatment and challenge of mice lacking the type I interferon 
receptor (and thus an interferon response) showed that 244/PR8-mediated protection against 
PVM requires a functional interferon system.  This is in marked contrast to the situation 
where wild type mice and mice lacking the type I interferon receptor were challenged with 
influenza A virus, and both were completely protected.  Our data demonstrate that the 
mechanism of protection from homologous and unrelated viruses differs, and that interferon 
type I is an essential component only of protection against genetically unrelated viruses.  
Consistent with this, 244/PR8 did not interfere with PVM multiplication in vitro (data not 
shown).  A further difference is that homologous protection also lasts longer, with a single 
dose providing protection for up to 6 weeks [1]. 
244/PR8 given 1 day before infection protects more efficiently from PVM-induced disease 
than when given simultaneously with PVM, which is consistent with the requirement for 
induction of interferon and the anti-viral state (data not shown), the duration of 244/PR8-
mediated protection against PVM, and effective life of 244/PR8-induced interferon in the 
lungs were similar (approximately 2-3 days).  The fact that 10-fold less intranasal 244/PR8 
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protects mice but does not induce detectable interferon suggests that the in vitro assay is a less 
efficient measure of antiviral activity than protection in vivo and that the local concentration 
of interferon at the site of infection is sufficiently high to provide protection.  A striking 
feature of the pathogenesis of the PVM infection in interferon receptor knockout mice was a 
consistent 4-day delay in the onset of disease, which suggests that the protecting 244/PR8 is 
also stimulating additional unknown factor(s) that contribute to protection (Fig. 4c, d). 
In support of the PVM data we found that 244/PR8 also protects against the genetically 
unrelated influenza B virus in vivo through stimulation of type I interferon (Fig. 6 and 
unpublished data).  Thus a single dose of 244/PR8 protects in vivo from infection with two 
genetically unrelated viruses by stimulating interferon type I, and possibly other elements of 
innate immunity.  Direct administration of type I interferon  has been shown to protect mice 
against a lethal challenge with influenza A virus [39, 40]. Protection against disease has also 
been demonstrated in ferrets treated with multiple doses of interferon  administered before 
and during infection with seasonal human influenza viruses but not with highly pathogenic 
H5N1 avian influenza [41].  With the seasonal influenza strains, virus titres in the lung were 
not altered by the treatment.  A recent human trial of intranasal treatment with low doses of 
interferon 2B showed evidence of protection against infection caused by influenza A virus, 
influenza B virus, parainfluenza viruses 1-3 and species B adenovirus but there was no effect 
on respiratory syncytial virus infection [42]. 
Despite the significant protection afforded against PVM disease by 244/PR8, replication of 
PVM was not completely eliminated.  There was evidently sufficient replication to induce a 
protective immune response to rechallenge with PVM.  Thus, in effect, DI virus treatment 
converts the lethal PVM disease into an avirulent, immunizing infection. 
The ability of interferon type I to protect mice from PVM is not surprising as type I 
interferons, defined by their use of a common cell surface receptor, are active in combatting 
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virus infections [43-45].  While stimulation of interferon type I by DI viruses has been 
reported to date it has been seen only in cultured cells with the double-stranded copyback and 
snapback DI RNAs of vesicular stomatitis virus and Sendai virus [27-31].  No animal 
protection studies have been published with copyback and snapback DI viruses, and the role 
that their double stranded DI RNAs and interferon may play in ameliorating disease is not 
known.  It is important to note that influenza DI RNAs do not possess large regions of double-
stranded sequence, and influenza viruses do not produce copyback or snapback DI RNAs that 
would be anticipated to induce high levels of interferon. 
Which of the components of the 244/PR8 particle is responsible for the interferon induction 
can only be surmised at present.  UV-inactivated 244/PR8 retains virion structure, 
haemagglutination and neuraminidase activities, and does not protect mice or stimulate 
interferon, suggesting that none of these factors are involved.  We are currently investigating 
the ability of other DI preparations to assess whether the level of interferon induction 
correlates with protection from infection.  The 244 RNA has approximately 80% of the 
central coding region of virion RNA segment 1 deleted and is unable to make PB2, an 
essential protein component of the viral RNA-dependent RNA polymerase.  Hence, there can 
be no de novo production of negative sense 244 RNA or any of the full-length RNAs present 
in the 244/PR8 virion in the absence of helper virus. 
In conclusion, we have shown that the influenza virus-derived, molecularly cloned 244/PR8 is 
capable of inducing type I interferon in vivo and that this can protect against disease from a 
genetically unrelated virus.  However, interferon induction is not required for protection 
against a homologous influenza A virus infection.  The protection afforded by 244/PR8 has 
clinical benefit against a lethal infection within a window of 3 days before infection to 2 days 
after infection.  Its advantages as an antiviral are its efficacy, single dosage, low amount of 
material, immediate effect, and protection regardless of antigenicity of the infecting virus.  DI 
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244/PR8 may therefore be of benefit in the prophylaxis and treatment of other respiratory 
viruses that are sensitive to type I interferon, in addition to providing protection from type A 
influenza viruses.  These observations demonstrate that DI RNAs may provide an additional 
and novel approach to antiviral therapy with little opportunity for the development of 
resistance in the target viruses. 
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Figure legends 
 
Fig. 1.  A single dose of influenza A 244/PR8 protects mice from PVM infection.  C3H/He-
mg mice were anaesthetized and inoculated intranasally with 244/PR8 or inactivated 244/PR8 
(day -1, solid arrow), and with PVM challenge virus (day 0, open arrow).  Panel (a) shows the 
clinical score, (b) PVM lung infectivity, and (c, d) percentage group weight change.  The 
clinical score is the averaged clinical evaluation for an experimental group as described in 
Methods.  In panel (a) the 244/PR8 alone control has a score of 1 and is hidden under the 
solid square symbols.  In panels (a) and (d) the inactivated 244/PR8 + PVM group followed 
the same clinical course as a PVM control, and a control group given diluent only exhibited 
no adverse affect (not shown).  In panels (c) and (d) group weights are presented as a 
percentage weight change normalised to the group weight on day 0 and are recorded up to the 
first death.  In panel (b) error bars show the standard deviation from the mean of PVM lung 
infectivity; those not apparent fall within the symbol.  Arrows indicate that infectivity was not 
detected.  No infectivity was detected in mice given 244/PR8 alone.  ■, 1.2 µg 244/PR8 + 
PVM; , 0.12 µg 244/PR8 + PVM; -, 0.012 µg 244/PR8 + PVM; ▲, 1.2 µg inactivated 
244/PR8 + PVM; ♦, PVM alone; ●, 1.2 µg 244/PR8 alone.  There were 5 mice per infected 
group.  The percentage of mice surviving each treatment is in parenthesis.  Data are 
representative of two experiments.  
 
Fig. 2.  Duration of protection afforded by influenza A 244/PR8 against PVM infection.  
C3H/He-mg mice were inoculated with 244/PR8 (solid arrow) 1 day (a, b) or 3 days (c, d) 
before challenge with PVM (open arrow).  Mice received 1.2 µg 244/PR8.  (a, c), clinical 
score, (b, d) percentage weight change.  ■, PVM + 244/PR8; ♦, PVM alone; ●, 244/PR8 
alone.  Data are representative of two experiments. 
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Fig. 3.  Therapeutic efficacy of influenza A 244/PR8 against PVM infection.  C3H/He-mg 
mice were infected with PVM at time 0 (open arrow).  A single dose of 244/PR8 (1.2 µg) was 
administered at 0, 1, 2 or 3 days after infection (solid arrows) with PVM.  Panel (a) shows the 
clinical score, and panel (b) the percentage weight change.  ■, PVM + 244/PR8 at time 0; , 
PVM + 244/PR8 at 24 h after infection; ♦, PVM + 244/PR8 at 48 h after infection; ◊, PVM + 
244/PR8 at 72 h after infection; ,  244/PR8 only at time 0.  Control groups given diluent 
exhibited no weight loss or adverse clinical signs (not shown).  Other information as in Fig. 1.  
 
Fig. 4.  Mice lacking the type I interferon receptor were protected poorly by influenza A 
244/PR8 against PVM infection, but protected strongly by 244/PR8 against influenza A/WSN 
infection.  PVM data are shown in panels (a) to (d), and A/WSN data in panels (e) to (h); 
129Sv/Ev wild type mice: panels (a), (b), (e) and (f), and knock-out 129Sv/Ev IFNα/βR-/- 
mice: panels (c), (d), (g) and (h).  Mice were treated with 1.2 µg of either 244/PR8 or UV 
inactivated 244/PR8 (solid arrow) 1 day before challenge with PVM or simultaneously with 
A/WSN (both open arrows).  All inoculations were intranasal.  Scores for clinical disease are 
shown in panels (a), (c), (e) and (g) and for percentage weight change in panels (b), (d), (f) 
and (h).   ■, 244/PR8 + PVM or A/WSN; ▲, inactivated 244/PR8 + PVM or A/WSN; ♦, 
PVM or A/WSN alone; ●, 244/PR8 alone.  A control group given only diluent had no adverse 
clinical signs or weight loss (not shown).  Diluent alone gave a similar result to 244/PR8, and 
A/WSN alone gave a similar result to A/WSN + inactivated 244/PR8 (not shown).  Other 
information as in Fig. 1.  
 
Fig. 5.  Identification of the virus-inhibiting activity stimulated in mice by 244/PR8 as 
interferon type I.  L929 cell monolayers were incubated with antibody (Ab, 10µg/well) to the 
 24 
mouse interferon type I-α/β receptor for 1 hour at 37°C, and then with the appropriate lung 
tissue extract (1/10 dilution) or an interferon-α standard preparation (10 units/well) for 24 
hours.  Cells were then inoculated with Chandipura virus (CV) and incubated for a 48 hours at 
33°C.  Survival of cells was determined by staining with crystal violet and measuring 
absorbance at 590 nm. Each error bar represents the standard deviation from the mean. 
 
Fig. 6.  Summary of heterologous and homologous protection exerted by influenza A virus 
244/PR8. 
 
 
